Case study: Study published in Biomolecules on the effects of MSC-sEV in skin fibrosis of BLM-SSc model.
We introduce a case study of drug efficacy evaluation of Mesenchymal stem/stromal cell-derived small extracellular vesicles (MSC-sEVs) using our Systemic sclerosis (SSc) model, BLM-SSc model.
Title: An Assessment of Administration Route on MSC-sEV Therapeutic Efficacy
( Zhang B et al., Biomolecules. 2024 ) Article Link ► [DOI: 10.3390/biom14060622]
In this study, we administered intraperitoneally, subcutaneously, or applied topically MSC-sEVs to the BLM-SSc model and evaluated the thickness of the dermis and adipose layer by HE staining and fibrotic areas of the skin by Masson’s trichrome-staining.
The results showed that skin fibrosis was significantly reduced in the MSC-sEVs treatment group compared to the control group and the positive control (Imatinib) group.
As in this study, we can provide studies to evaluate the drug efficacy of cell therapy methods such as MSC-sEVs, as well as basic research on skin fibrosis and scleroderma using the SSc model.
We use our original method of bleomycin administration to induce the disease uniformly.
For more information, please click here ▶▶▶ 【 About BLM-SSc Model 】
If you are interested in our BLM-SSc model or other fibrotic disease models or have any questions, please feel free to contact us.